# Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer

> **NCT03084237** · PHASE3 · COMPLETED · sponsor: **Shanghai Henlius Biotech** · enrollment: 652 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** HLX02
- **BIOLOGICAL:** Herceptin®
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT03084237
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2018-11-23
- **Final completion:** 2021-09-28
- **Target enrollment:** 652 (ACTUAL)
- **Last updated:** 2024-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03084237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03084237, "Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03084237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*